What are the specific effects of Mitotane tablets?

Mitotane tablets are a targeted drug specifically targeted at adrenocortical diseases. Its main function is to inhibit the function and growth of adrenocortical cells, so that abnormal hormone secretion can be effectively controlled. It is widely used in the treatment of patients with unresectable functional or non-functioning adrenocortical carcinoma (ACC; adrenal carcinoma) and has also shown important value in the management of Cushing's syndrome. For patients with functional ACC, mitotane can significantly improve symptoms such as hypertension, obesity, glucose metabolism disorders, and osteoporosis caused by excess hormones by inhibiting the synthesis and secretion of adrenocortical hormones, thereby improving the patient's quality of life.

The mechanism of action of Mitotane is relatively unique. It reduces the proliferation ability of adrenocortical cells through direct toxic effects on adrenocortical cells, thereby delaying tumor progression. Compared with drugs that only treat symptoms, mitotane can both inhibit hormone secretion and have a certain anti-tumor effect, so it is particularly important in inoperable patients. For patients with Cushing's syndrome, mitotane can help control excess cortisol levels and alleviate pathological symptoms. Overseas guidelines point out that mitotane has become one of the irreplaceable drug options in the long-term management of ACC and related endocrine diseases.

When using mitotane, patients need to adjust the dosage strictly in accordance with the doctor's instructions to ensure that the drug works within the effective range while avoiding potential toxicity. Regular monitoring of blood drug concentration, liver and kidney function, and blood lipid levels is an important part of maintaining treatment safety. In addition, patients should pay attention to diet and lifestyle management during treatment to reduce the physical burden caused by drug side effects and hormonal disorders.

Taken together, mitotane can not only provide an important treatment for patients with inoperableACC, but also provide effective pharmaceutical support for the control of Cushing's syndrome. Its clinical value and application potential have been recognized in multiple overseas guidelines.

Reference materials:https://go.drugbank.com/drugs/DB00648